Cargando…
Case Report: Anti-LGI1 Encephalitis Following COVID-19 Vaccination
Anti-leucine rich glioma inactivated 1 (LGI1) autoimmune encephalitis (AE) is characterized by cognitive impairment or rapid progressive dementia, psychiatric disorders, faciobrachial dystonic seizures (FBDS) and refractory hyponatremia. Since December 2020, millions of people worldwide have been va...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766789/ https://www.ncbi.nlm.nih.gov/pubmed/35069602 http://dx.doi.org/10.3389/fimmu.2021.813487 |
_version_ | 1784634601665200128 |
---|---|
author | Zlotnik, Yair Gadoth, Avi Abu-Salameh, Ibrahim Horev, Anat Novoa, Rosa Ifergane, Gal |
author_facet | Zlotnik, Yair Gadoth, Avi Abu-Salameh, Ibrahim Horev, Anat Novoa, Rosa Ifergane, Gal |
author_sort | Zlotnik, Yair |
collection | PubMed |
description | Anti-leucine rich glioma inactivated 1 (LGI1) autoimmune encephalitis (AE) is characterized by cognitive impairment or rapid progressive dementia, psychiatric disorders, faciobrachial dystonic seizures (FBDS) and refractory hyponatremia. Since December 2020, millions of people worldwide have been vaccinated against COVID-19. Several soft neurological symptoms like pain, headache, dizziness, or muscle spasms are common and self-limited adverse effects after receiving the COVID-19 vaccine. However, several major neurological complications, despite the unproven causality, have been reported since the introduction of the COVID-19 vaccine. Herein, we describe a 48 years old man presenting with rapidly progressive cognitive decline and hyponatremia diagnosed with anti LGI1 AE, occurring shortly after the second dose of mRNA COVID -19 vaccine and possibly representing a severe adverse event related to the vaccination. Response to high dose steroid therapy was favorable. As millions of people worldwide are currently receiving COVID-19 vaccinations, this case should serve to increase the awareness for possible rare autoimmune reactions following this novel vaccination in general, and particularly of anti-LGI1 AE. |
format | Online Article Text |
id | pubmed-8766789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87667892022-01-20 Case Report: Anti-LGI1 Encephalitis Following COVID-19 Vaccination Zlotnik, Yair Gadoth, Avi Abu-Salameh, Ibrahim Horev, Anat Novoa, Rosa Ifergane, Gal Front Immunol Immunology Anti-leucine rich glioma inactivated 1 (LGI1) autoimmune encephalitis (AE) is characterized by cognitive impairment or rapid progressive dementia, psychiatric disorders, faciobrachial dystonic seizures (FBDS) and refractory hyponatremia. Since December 2020, millions of people worldwide have been vaccinated against COVID-19. Several soft neurological symptoms like pain, headache, dizziness, or muscle spasms are common and self-limited adverse effects after receiving the COVID-19 vaccine. However, several major neurological complications, despite the unproven causality, have been reported since the introduction of the COVID-19 vaccine. Herein, we describe a 48 years old man presenting with rapidly progressive cognitive decline and hyponatremia diagnosed with anti LGI1 AE, occurring shortly after the second dose of mRNA COVID -19 vaccine and possibly representing a severe adverse event related to the vaccination. Response to high dose steroid therapy was favorable. As millions of people worldwide are currently receiving COVID-19 vaccinations, this case should serve to increase the awareness for possible rare autoimmune reactions following this novel vaccination in general, and particularly of anti-LGI1 AE. Frontiers Media S.A. 2022-01-05 /pmc/articles/PMC8766789/ /pubmed/35069602 http://dx.doi.org/10.3389/fimmu.2021.813487 Text en Copyright © 2022 Zlotnik, Gadoth, Abu-Salameh, Horev, Novoa and Ifergane https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zlotnik, Yair Gadoth, Avi Abu-Salameh, Ibrahim Horev, Anat Novoa, Rosa Ifergane, Gal Case Report: Anti-LGI1 Encephalitis Following COVID-19 Vaccination |
title | Case Report: Anti-LGI1 Encephalitis Following COVID-19 Vaccination |
title_full | Case Report: Anti-LGI1 Encephalitis Following COVID-19 Vaccination |
title_fullStr | Case Report: Anti-LGI1 Encephalitis Following COVID-19 Vaccination |
title_full_unstemmed | Case Report: Anti-LGI1 Encephalitis Following COVID-19 Vaccination |
title_short | Case Report: Anti-LGI1 Encephalitis Following COVID-19 Vaccination |
title_sort | case report: anti-lgi1 encephalitis following covid-19 vaccination |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766789/ https://www.ncbi.nlm.nih.gov/pubmed/35069602 http://dx.doi.org/10.3389/fimmu.2021.813487 |
work_keys_str_mv | AT zlotnikyair casereportantilgi1encephalitisfollowingcovid19vaccination AT gadothavi casereportantilgi1encephalitisfollowingcovid19vaccination AT abusalamehibrahim casereportantilgi1encephalitisfollowingcovid19vaccination AT horevanat casereportantilgi1encephalitisfollowingcovid19vaccination AT novoarosa casereportantilgi1encephalitisfollowingcovid19vaccination AT iferganegal casereportantilgi1encephalitisfollowingcovid19vaccination |